Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Medicine, Internal medicine, Oncology, NPM1, Gemtuzumab ozogamicin, and Cytarabine.
Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in <i>FLT3</i> -mutated AML
Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AML
Postinduction molecular MRD identifies patients with <i>NPM1</i> AML who benefit from allogeneic transplant in first remission
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial